Journal Article DKFZ-2017-04212

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2014
Springer Berlin

Acta neuropathologica 128(4), 551 - 559 () [10.1007/s00401-014-1326-7]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Astrocytoma and oligodendroglioma are histologically and genetically well-defined entities. The majority of astrocytomas harbor concurrent TP53 and ATRX mutations, while most oligodendrogliomas carry the 1p/19q co-deletion. Both entities share high frequencies of IDH mutations. In contrast, oligoastrocytomas (OA) appear less clearly defined and, therefore, there is an ongoing debate whether these tumors indeed constitute an entity or whether they represent a mixed bag containing both astrocytomas and oligodendrogliomas. We investigated 43 OA diagnosed in different institutions employing histology, immunohistochemistry and in situ hybridization addressing surrogates for the molecular genetic markers IDH1R132H, TP53, ATRX and 1p/19q loss. In all but one OA the combination of nuclear p53 accumulation and ATRX loss was mutually exclusive with 1p/19q co-deletion. In 31/43 OA, only alterations typical for oligodendroglioma were observed, while in 11/43 OA, only indicators for mutations typical for astrocytomas were detected. A single case exhibited a distinct pattern, nuclear expression of p53, ATRX loss, IDH1 mutation and partial 1p/19q loss. However, this was the only patient undergoing radiotherapy prior to surgery, possibly contributing to the acquisition of this uncommon combination. In OA with oligodendroglioma typical alterations, the portions corresponding to astrocytic part were determined as reactive, while in OA with astrocytoma typical alterations the portions corresponding to oligodendroglial differentiation were neoplastic. These data provide strong evidence against the existence of an independent OA entity.

Keyword(s): Nuclear Proteins ; Tumor Suppressor Protein p53 ; Isocitrate Dehydrogenase ; IDH1 protein, human ; DNA Helicases ; ATRX protein, human

Classification:

Contributing Institute(s):
  1. KKE Neuropathologie (G380)
  2. Pädiatrische Neuroonkologie (B062)
  3. KKE Neuroonkologie (G370)
  4. DKTK Heidelberg (L101)
  5. DKTK Tübingen (L801)
Research Program(s):
  1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2014
Database coverage:
Medline ; BIOSIS Previews ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2017-10-12, last modified 2024-02-28



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)